The first BCL-2-selective BH3 mimetic to be tested and approved, venetoclax [8], can be dosed in patients to effectively inhibit BCL-2 and drive robust anti-tumor efficacy [9,10,11]. The gene discussed is BCL2; the disease is neoplasm.